Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyThe Addition of Darolutamide to Androgen Deprivation Therapy and Docetaxel in a 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer

In this 3rd case in a short series, the author describes integration of next-generation PSMA imaging with conventional imaging, including CT and bone scans. The author reviews the rationale for triple therapy with darolutamide, ADT, and docetaxel, and reviews the key phase III studies on triple therapy in prostate cancer: the ENZAMET, PEACE-1 and ARASENS trials.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form